Company Investors Technology Careers Updates Events Contact Latest updates In the press Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with Janssen Latest from @ExonateUK https://t.co/5IjTv3MmrS All updates In the press Insights Company news Awards Latest updates 1 2 3 4 5 Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia